Page last updated: 2024-12-07
resorufin galactopyranoside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
resorufin galactopyranoside: fluorogenic substrate for beta-galactosidase activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 125273 |
| SCHEMBL ID | 16069592 |
| MeSH ID | M0158620 |
Synonyms (22)
| Synonym |
|---|
| resorufin beta-d-galactopyranoside |
| 7-(beta-d-galactopyranosyloxy)-3h-phenoxazin-3-one |
| resorufin beta-d-galactopyranoside, ~95% |
| 7-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenoxazin-3-one |
| AKOS015916747 |
| 95079-19-9 |
| 3h-phenoxazin-3-one, 7-(beta-d-galactopyranosyloxy)- |
| resorufin galactopyranoside |
| resorufin |a-d-galactopyranoside |
| 3h-phenoxazin-3-one,7-(b-d-galactopyranosyloxy)- |
| mfcd00064055 |
| SCHEMBL16069592 |
| resorufin-i(2)-d-galactopyranoside |
| DTXSID30241747 |
| 7-(((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-3h-phenoxazin-3-one |
| 7-((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-3h-phenoxazin-3-one |
| resorufin beta -d-galactopyranoside |
| res-gal |
| STARBLD0016675 |
| CS-0137345 |
| resorufin-|a-d-galactopyranoside |
| HY-137249 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " By means of the dose-response curve of PN of a hops' remainder extract, the estradiol equivalent concentration (EEQ) and thus the estradiol equivalent amount (EEA) of PN in the hops' remainder after simulation of the wort boiling was determined to 39 μg/L and 52 μg/kg, respectively." | ( Detection of estrogen active compounds in hops by planar yeast estrogen screen. Schick, D; Schwack, W, 2018) | 0.48 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.06
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.06) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||